BNP Paribas Financial Markets Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

BNP Paribas Financial Markets purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,218 shares of the company's stock, valued at approximately $304,000.

Other large investors also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd raised its position in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after buying an additional 553 shares during the last quarter. Virtus ETF Advisers LLC raised its position in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares during the last quarter. Assetmark Inc. raised its position in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Structure Therapeutics by 673.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock worth $111,000 after buying an additional 3,549 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Structure Therapeutics during the 4th quarter worth $113,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have commented on GPCR. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating for the company. Citigroup started coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target for the company. Finally, HC Wainwright cut their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a report on Monday, May 12th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and a consensus price target of $79.86.

Structure Therapeutics Stock Performance

NASDAQ GPCR traded down $0.70 during trading hours on Friday, reaching $21.72. The company's stock had a trading volume of 731,220 shares, compared to its average volume of 941,585. The stock has a market cap of $1.25 billion, a PE ratio of -29.35 and a beta of -1.69. Structure Therapeutics Inc. has a fifty-two week low of $13.22 and a fifty-two week high of $62.74. The company's 50-day moving average is $21.69 and its two-hundred day moving average is $25.34.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.